Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Epirubicin Clear all
Active, not recruiting Phase 3 Interventional

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

NCT03281954
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Placebo, Atezolizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
1,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
212
States / cities
Mobile, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 164 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

NCT03036488
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
47
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

NCT00110695
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Nanoparticle albumin bound paclitaxel followed by FEC
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2010 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 25, 2026, 2:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

NCT00667420
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions
panitumumab, epirubicin, oxaliplatin, xeloda
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

NCT00017186
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
epirubicin hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 25, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

NCT03498716
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Concord, California • Los Angeles, California • St. Helena, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

NCT00193206
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Fort Myers, Florida • Jacksonville, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

NCT00058487
View directory record Official record
Conditions
Liver Cancer
Interventions
epirubicin hydrochloride, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

NCT00270894
View directory record Official record
Conditions
Breast Neoplasm
Interventions
epirubicin, cyclophosphamide, docetaxel, trastuzumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 25, 2026, 2:43 AM EDT
Withdrawn Phase 3 Interventional

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

NCT01327521
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
CyberKnife, TACE, CT Contrast, doxorubicin, Epirubicin, 5-fluorouracil, Mitomycin C, Gemcitabine, Cisplatin, SMANCS
Device · Procedure · Drug
Lead sponsor
Albert Koong
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

NCT01358877
View directory record Official record
Conditions
Breast Cancer
Interventions
5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
4,804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
114
States / cities
Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer

NCT00020748
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epirubicin hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

NCT00038402
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Taxol, Fluorouracil, Cytoxan, Epirubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 25, 2026, 2:43 AM EDT
Withdrawn Phase 2 Interventional

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

NCT02067416
View directory record Official record
Conditions
Breast Cancer
Interventions
Anthracycline based chemotherapy, taxane-based chemotherapy
Drug
Lead sponsor
Jenny C. Chang, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

NCT00878904
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epirubicin hydrochloride, panobinostat, gene expression analysis, protein expression analysis, western blotting, immunologic technique, laboratory biomarker analysis, pharmacological study
Drug · Genetic · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 25, 2026, 2:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
58
States / cities
Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00096304
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, epirubicin hydrochloride
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 25, 2026, 2:43 AM EDT
Terminated Not applicable Interventional Results available

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

NCT02358863
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan, Cisplatin/Docetaxel, IRI/EPI, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

NCT00087178
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, adriamycin, epirubicin, fluorouracil
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
2,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
586
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 396 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

NCT00140075
View directory record Official record
Conditions
Adenocarcinoma
Interventions
Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin with a Taxane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
54
States / cities
Mobile, Alabama • Tucson, Arizona • Bakersfield, California + 49 more
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Not applicable Interventional

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

NCT00617370
View directory record Official record
Conditions
Breast Cancer, Adenocarcinoma of the Breast
Interventions
epirubicin, cyclophosphamide, Paclitaxel,
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 25, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

NCT01624441
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 25, 2026, 2:43 AM EDT